(Q43655193)

25 November 2017

title

Once-daily budesonide via Turbuhaler improves symptoms in adults with persistent asthma (English)

1 reference

25 November 2017

0 references

Banov CH

1

1 reference

25 November 2017

Howland WC 3rd

series ordinal

2

1 reference

25 November 2017

Lumry WR

series ordinal

3

1 reference

25 November 2017

publication date

1 June 2001

1 reference

Annals of Allergy, Asthma & Immunology

25 November 2017

published in

1 reference

25 November 2017

volume

86

1 reference

25 November 2017

issue

6

1 reference

25 November 2017

page(s)

627-632

1 reference

Budesonide. An updated review of its pharmacological properties, and therapeutic efficacy in asthma and rhinitis

25 November 2017

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962290-9

7 January 2021

Lung deposition of budesonide from Turbuhaler is twice that from a pressurized metered-dose inhaler P-MDI

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962290-9

7 January 2021

Budesonide delivered by Turbuhaler is effective in a dose-dependent fashion when used in the treatment of adult patients with chronic asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962290-9

7 January 2021

Rapid onset of control with budesonide Turbuhaler in patients with mild-to-moderate asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962290-9

7 January 2021

Oral glucocorticosteroid-sparing effect of budesonide administered by Turbuhaler: a double-blind, placebo-controlled study in adults with moderate-to-severe chronic asthma. Pulmicort Turbuhaler Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962290-9

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962290-9

7 January 2021

Nonadherence in asthmatic patients: is there a solution to the problem?

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962290-9

7 January 2021

Measuring compliance with inhaled medication in asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962290-9

7 January 2021

Compliance with inhaled therapy and morbidity from asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962290-9

7 January 2021

Administration of budesonide once daily by means of turbuhaler to subjects with stable asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962290-9

7 January 2021

Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD) and asthma. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, November 1986

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962290-9

7 January 2021

Results of pulmonary valvotomy and infundibular resection in 100 cases of Fallot's tetralogy

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962290-9

7 January 2021

Pulmicort Turbohaler once daily as initial prophylactic therapy for asthma

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962290-9

7 January 2021

A Comparison of the Effects of bid and qid Dosing on Compliance with Inhaled Flunisolide

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962290-9

7 January 2021

Once-daily versus twice-daily dosing of theophylline. A decision analysis approach to evaluating theophylline blood levels and compliance

1 reference

https://api.crossref.org/works/10.1016%2FS1081-1206%2810%2962290-9

7 January 2021

10.1016/S1081-1206(10)62290-9

Identifiers

DOI

1 reference

25 November 2017

1 reference